BridgeBio 报告 2025 年第三季度财务业绩和业务更新

- $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - Attruby continues to differentiate clinically by proving its unique profile in new subpopulations and holistic analyses: -JACC publication demonstrated the effect of Attruby on cumulative cardiovascular outcomes within the first month of treatment -Positive topline interim analysis results from FORTIFY, the registrational Phase 3 study of BBP-418, a small molecule in development for LGMD2I/R9 -Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p